General information

Announcements(1)

Program

Sessions

Search presentations

Download PDF for print

Timetable

Mon. Mar 17, 2025

Tue. Mar 18, 2025

Wed. Mar 19, 2025

web_header_en.png

web_icon.png

Profile management

Announcements

Bookmark

Program Type

Login required to view

Password required to view

Presentation Information

Session Details

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

The prefrontal dopaminergic system underlies stress resilience and antidepressant effects of ketamine

Many stress-related disorders, including major depressive disorder and post-traumatic stress disorder (PTSD), are not adequately treated with currently available antidepressants and anxiolytics due to the complexity of their pathophysiology. Recently, considerable research and development efforts are being made to develop novel therapeutic agents based on mechanisms different from conventional monoaminergic antidepressants and benzodiazepine anxiolytics, as evidenced by clinical reports demonstrating the efficacy of the NMDA receptor antagonist ketamine in treatment-resistant depression and PTSD. In addition, studies on the mechanisms of stress resilience (resistance to and recovery from stress) have been actively conducted. This symposium aims to introduce and discuss novel therapeutic targets identified mainly through mouse studies focusing on the pathophysiology of stress-related disorders, the neural mechanisms of stress resilience, those underlying the effects of exercise on emotion, and the mechanisms of action of drug candidates.

Discovery of novel therapeutic targets for stress-related disorders

APPW2025

Presentation Information

[[OD]3S14a-2]The prefrontal dopaminergic system underlies stress resilience and antidepressant effects of ketamine

Login required to view

Comment